To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma
Age 18-80 years, no gender restrictions;
Diagnosed with refractory/relapsed multiple myeloma through physical examination, pathological examination, laboratory tests, and imaging studies;
Flow cytometry or histology confirms positive BCMA expression in myeloma cells;
As judged by the investigator, the expected survival time is >3 months;
Pregnant or nursing women, as well as women planning to become pregnant within the next six months;
Positive virology tests for hepatitis B, hepatitis C, HIV, syphilis, or cytomegalovirus;
History of other tumors (except for those with skin or cervical in situ cancers that have been cured by radical treatment and show no evidence of disease activity);
Previously received treatment targeting BCMA;